Last reviewed · How we verify
Unresectable malignant melanoma with BRAF gene mutation
Approved treatments
- Mektovi · Pfizer
Mektovi works by blocking a specific enzyme called MEK1, which is involved in sending signals that promote cancer cell growth. - Mektovi · Pfizer
Mektovi works by blocking the MEK1 enzyme, which is a key player in the signaling pathway that promotes cancer cell growth. - Braftovi · Pfizer
Braftovi works by blocking the activity of a specific protein called BRAF that is involved in cancer cell growth.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Unresectable malignant melanoma with BRAF gene mutation patent landscape — cliff calendar, originator estates, attackable patents
- Unresectable malignant melanoma with BRAF gene mutation treatment landscape brief
- Unresectable malignant melanoma with BRAF gene mutation treatment updates RSS
Frequently asked questions about Unresectable malignant melanoma with BRAF gene mutation
What drugs treat Unresectable malignant melanoma with BRAF gene mutation?
Tracked treatments include Mektovi, Braftovi.
What is the treatment for Unresectable malignant melanoma with BRAF gene mutation?
Standard treatment for Unresectable malignant melanoma with BRAF gene mutation includes Mektovi, Braftovi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Unresectable malignant melanoma with BRAF gene mutation patent cliff · Unresectable malignant melanoma with BRAF gene mutation CI report
- Treatment: Mektovi · Pfizer
- Treatment: Mektovi · Pfizer
- Treatment: Braftovi · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing